INCYTE CORP's ticker is INCY and the CUSIP is 45337C102. A total of 527 filers reported holding INCYTE CORP in Q3 2022. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ADAMS DIVERSIFIED EQUITY FUND, INC. | 304,300 | $20,279,000 | 1.01% |
| DODGE & COX | 19,793,400 | $1,319,032,000 | 1.00% |
| COUNTRY TRUST BANK | 442,256 | $29,472,000 | 0.92% |
| CTC Capital Management, LLC | 17,200 | $1,146,000 | 0.92% |
| Gs Investments, Inc. | 20,000 | $1,333,000 | 0.88% |
| Machina Capital S.A.S. | 6,151 | $410,000 | 0.87% |
| GREENWOOD CAPITAL ASSOCIATES LLC | 68,332 | $4,554,000 | 0.78% |
| JGP Global Gestao de Recursos Ltda. | 13,192 | $879,000 | 0.74% |
| GRIMES & COMPANY, INC. | 202,763 | $13,512,000 | 0.70% |
| Sivik Global Healthcare LLC | 18,755 | $1,250,000 | 0.70% |
| EFG Asset Management (North America) Corp. | 45,024 | $3,000,000 | 0.69% |
| SEEYOND | 83,180 | $5,543,000 | 0.67% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 1,156,285 | $77,055,000 | 0.61% |
| PARTNERS CAPITAL INVESTMENT GROUP, LLP | 151,446 | $10,092,000 | 0.60% |
| Empirical Asset Management, LLC | 7,830 | $522,000 | 0.57% |
| PRINCETON CAPITAL MANAGEMENT LLC | 16,894 | $1,126,000 | 0.49% |
| Polar Capital Holdings Plc | 1,158,298 | $77,189,000 | 0.49% |
| ARK Investment Management | 1,030,189 | $68,652,000 | 0.48% |
| Renaissance Technologies | 4,847,233 | $323,020,000 | 0.46% |
| Knott David M Jr | 16,257 | $1,083,000 | 0.46% |
About INCYTE CORP
Incyte Corp is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel medicines to meet the unmet medical needs of patients. The company has a diverse portfolio of products that are designed to treat a range of diseases, including cancer, autoimmune disorders, and inflammatory conditions.
One of the company's most promising products is Jakafi, a drug that is used to treat patients with myelofibrosis, a rare type of blood cancer. Jakafi has been approved by the FDA and is currently being used by patients around the world. The drug has also shown promise in treating other types of cancers, including pancreatic cancer and acute graft-versus-host disease.
Incyte Corp has a strong pipeline of products that are in various stages of development. The company is currently conducting clinical trials for several products, including ruxolitinib cream, a topical treatment for atopic dermatitis, and pemigatinib, a drug that is being developed to treat cholangiocarcinoma, a type of liver cancer.
The company has a strong management team that is focused on delivering value to shareholders. The CEO, Hervé Hoppenot, has a proven track record of success in the biopharmaceutical industry and has been instrumental in driving the company's growth.
Overall, Incyte Corp is a company that is well-positioned for long-term success. With a strong portfolio of products, a robust pipeline, and a talented management team, the company is poised to continue delivering value to patients and shareholders alike.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
External links
This page lists INCYTE CORP's shareholders in Q3 2022. To view INCYTE CORP's shareholder history, click here.